Review Article

Status of Epstein-Barr Virus Coinfection with Helicobacter pylori in Gastric Cancer

Shyam Singh and Hem Chandra Jha

Centre for Biosciences and Biomedical Engineering, Indian Institute of Technology, Indore, India

Correspondence should be addressed to Hem Chandra Jha; hemcjha@iiti.ac.in

Received 6 December 2016; Accepted 14 February 2017; Published 21 March 2017

Academic Editor: Bisweswar Nandi

Copyright © 2017 Shyam Singh and Hem Chandra Jha. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Epstein-Barr virus is a ubiquitous human herpesvirus whose primary infection causes mononucleosis, Burkett's lymphoma, nasopharyngeal carcinoma, autoimmune diseases, and gastric cancer (GC). The persistent infection causes malignancies in lymph and epithelial cells. Helicobacter pylori causes gastritis in humans with chronic inflammation. This chronic inflammation is thought to be the cause of genomic instability. About 45%-word population have a probability of having both pathogens, namely, H. pylori and EBV. Approximately 180 per hundred thousand population is developing GC along with many gastric abnormalities. This makes GC the third leading cause of cancer-related death worldwide. Although lots of research are carried out individually for EBV and H. pylori, still there are very few reports available on coinfection of both pathogens. Recent studies suggested that EBV and H. pylori coinfection increases the occurrence of GC as well as the early age of GC detection comparing to individual infection. The aim of this review is to present status on coinfection of both pathogens and their association with GC.

1. Introduction

Gastric cancer (GC) or stomach cancer is the fifth most common cancer incident and the third leading cause of cancer-associated mortality, contributing 6.8% of total cancer cases and 8.8% of total cancer-associated death worldwide [1]. An estimated 984,000 new cases (ratio 2:1, male versus female) and 841,000 GC-related deaths were accounted in 2013 [2]. Approximately, 77% of GC-related cases and the death occur in developing countries, particularly in Eastern Asia, while 23% occur in developed nations [2]. GC can be divided into 4 types on the basis of appearance in different cell types: (1) adenocarcinoma: within the cells of the innermost lining of the stomach (mucous surface); (2) lymphoma: cancer of the immune system in lymph stomach tissues, very rare; (3) gastrointestinal stromal tumors: stomach epithelial lining tumors in interstitial cells of Cajal, very rare; (4) carcinoid tumors: typically arising in the hormone-producing cells of the stomach. The common histopathological features of gastric malignancies are adenocarcinoma. It accounts for nearly 90% of GC [3]. Adenocarcinomas are further divided into two parts: (1) cardia, the top part of the stomach; (2) noncardia cancers, depending on location in the stomach where they first appear. H. pylori is now a well-known and primary cause of GC [4–10], specifically noncardia cancer [11, 12], and is declared as carcinogen I [13] to humans. H. pylori is now well known to be linked to stomach cancer in many studies along with EBV [14–18]. Other risk factors for GC include chronic gastritis [9], older age [19], male sex [20, 21], a diet high in salt [22–24], smoking [25, 26], alcohol consumption [27], poorly preserved foods [28], diet low in fruits and vegetables [29], tobacco product [30], pernicious anaemia [31–33], a history of stomach surgery for benign conditions [34], and a family history of stomach cancer [34, 35].

2. Clinical Association

GC arises mostly in mucosa, the innermost layer in the stomach, and slowly grows out into the other outer layers [58]. GC grows slowly over many years and rarely shows symptoms and is often unnoticed [59–61]. H. pylori is a spiral-shaped bacterium that grows in the mucus layer which coats the inside of the human stomach, ultimately causing inflammation in the stomach called gastritis [62]. Further, it turns to
EBV is associated with GC worldwide (11% male, 6% female) and widespread human tumors [15, 90–92]. Some of these tumors are associated with the virus lifestyle and behaviour in the B lymphoid system which is a natural niche of EBV, including B-lymphoproliferative disease [93, 94] in the immunocompromised individual [95], Hodgkin lymphoma [96], Burkitt's lymphoma [97, 98], and a subset of diffuse large B-cell lymphomas [99, 100]. Other tumors occur through viral entry into host's different organ tissues or system. These include nasal T/NK cell lymphoma [101, 102], a group of undifferentiated nasopharyngeal carcinomas (NPC) [103, 104], and gastric carcinomas [91, 92], a tumor type which is linked with chronic *H. pylori* infection through many years. *H. pylori* and EBV account for roughly 80% and 10%, respectively, of GC worldwide. EBV-associated GC is located in the cardia (58%), noncardia (42%) [105], while GC associated with only *H. pylori* is mostly noncardia type of adenocarcinoma [11, 106] (Figure 1).

### 3. EBV Detection Methods

#### 3.1. Serological Test

Serological tests for EBV are antibodies specific test with EBV antigens and used to define infection status. Three specific antibodies tests are as follows: (1) Anti-Viral Capsid Antigen (VCA) antibodies IgM and IgG: IgM can be detected in early stage of EBV infection and within 4 to 6 weeks disappears [107–109], while for IgG peaks can be detected within 2 to 4 weeks which decline slightly
and remain detectable throughout life [109]. (2) Anti-Early Antigen (EA) antibody IgG: IgG can be detected in the acute stage of infection such as mononucleosis or NPC and it disappears after 3 to 6 months [110]. Detection of Anti-EA IgG represents an active or reactivated EBV infection [111]. Nearly in 20% of people, Anti-EA IgG may be detected for years after resolution of active EBV infection [111, 112]. (3) Anti-EBV Nuclear Antigen (EBNA) 1 antibody, IgG: IgG can be detected after 2 to 4 months of primary EBV infection and remain detectable throughout life [112]. These antibodies tests are helpful to distinguish from acute to a past EBV infection [112, 113]. For example, detection of Anti-VCA IgG and IgM indicates active acute infection if Anti-EBNA 1 is not detected [112], while the detection of Anti-VCA IgG and Anti-EBNA IgG without presence of Anti-VCA IgM represents a past infection [112]. However, sometimes it becomes difficult to conclude when Anti-VCA IgG is detected while Anti-VCA IgM and Anti-EBNA are not. This may be a case of acute, past, or a recent infection [112]. Testing of one more parameter can be included to interpret result correctly, that is, detection of Anti-EA (D) IgG antibodies [114, 115]. During EBV reactivation, Anti-VCA IgG, Anti-EBNA 1, and Anti-EA (D) IgG may be detected simultaneously [112]. The serological results and interpretation are listed in Table 1.

3.2. PCR/Real-Time PCR Based Detection. EBV DNA and viral load can be detected by PCR/real-time PCR methods [116]. They are more sensitive and specific than serological methods as EBV immunologic response appears after several days of infections [117–119]. After 15-day onset of onset of EBV infection, 100% of EBV DNA is detectable in plasma [118]. Several reports suggested that EBV DNA is present in almost all carcinoma cells in EBV-positive cases [120]. After primary EBV infection due to immune response, EBV DNA declines slowly in PBMCs, rapidly in plasma or serum, and further 3 to 4 weeks, it becomes undetectable [118, 121]. Interestingly, EBV may remain latent in memory cells for an extended period in blood or take a longer time before it reaches a small, stable stage. Copy number range of 1 to 50 of EBV DNA may be detected in a healthy person infected with EBV in white blood cells (WBC) [122]. PCR and real-time PCR sensitivity and specificity vary based on detection methods as well as laboratory to laboratory practise [118, 123, 124].

4. Helicobacter pylori Detection Methods

Various methods have been developed to detect H. pylori infection, whereas the gold standard detection remains debatable [125]. In H. pylori epidemics study, the sensitivity of tests varies for the direct test (histopathology/IHC or rapid urease test); many noninvasive tests are developed which are called indirect test (serology, UBT, and SAT) to determine infection status [126].

4.1. Serological Test. Serological testing using patients’ blood and ELISA techniques to detect IgG, IgM, and IgA for H. pylori have been developed. Serological testing has uniformly high sensitivity (90 to 100%), variable specificity (76 to 96%), and the accuracy range between 83 and 98%; however, it does not discriminate between current infection or recent exposures [127, 128]. Serological tests require validation at the local level, which is impractical in routine practice. Moreover, serologic findings in both the children and adults are conflicting, and the cut-off is not shown to be accurate in many studies [129, 130]. Serological testing is accurate in low prevalence regions where less than 20% of the population are affected. In those patients where the gastric lining has not changed to the precancerous form of intestinal metaplasia, neither biopsy nor Urea Breath Tests can be used as there are very few bacteria present [131, 132]. Moreover, serial serology from antibody concentrations can be used as follow-up after treatment of H. pylori [133].

4.2. Urea Breath Test (UBT). UBT measures C13 carbon dioxide in breath after ingesting C-13-labelled urea [134]. This test is approved by FDA, USA. This can be used for the individuals aged 3 years or older. The cost of UBT is more than serological or stool antigen testing and UBT can be used both as a diagnostic tool and in efficacy of treatments [131, 132].

4.3. Stool Antigen Test (SAT). Antigens released from the wall of the stomach can be detected in SAT through ELISA. Detection of antigen only occurs if H. pylori is present and this shows active infection [135]. Similar to the UBT, the SAT can be used both as a diagnostic tool and in efficacy of treatments [125]. This is also an FDA-approved test and SAT is recommended by the ACG and the AGA [136, 137].

5. EBV Infection to Gastric Epithelial Cells

Latency and reactivation are the hallmarks of EBV which is a ubiquitous and potentially oncogenic human herpes virus [87]. EBV was discovered in 1964 in patients with Burkett’s lymphoma (BL) [138]. Initially, it was assumed that it infects only B-cells; later, it was also found in nasopharyngeal

| Table 1 | Anti-VCA IgM | Anti-VCA IgG | Anti-EBNA 1 IgG | Anti-EA (D) IgG | Interpretation |
|---------|-------------|-------------|----------------|----------------|---------------|
| −       | −           | −           | −              | −              | No infection  |
| +       | −           | −           | −              | −              | An early and primary infection |
| − or +  | +           | −           | +              | −              | An active infection |
| −       | +           | +           | −              | −              | A past infection |
| −       | +           | +           | +              | +              | May indicate reactivation of virus, lytic |

Serological results and most likely interpretation: VCA: Viral Capsid Antigen, IgM: immunoglobulin type M, IgG: Immunoglobulin type G, EBNA 1: Epstein–Barr nuclear antigens 1, EA (D): Early Antigen D.
epithelial cells [139], liver cells [136], stomach epithelial cells [91], brain cells [137], and so forth.

5.1. Low Tropism of EBV Infection through Oral Route to Mouth Oropharyngeal Epithelial Cells. Due to difficulties in establishing reproducible and robust infection in vitro, it is very difficult to simulate a real understanding of EBV pathology [114]. Most of the studies suggested that EBV may be transcytosed via EBV+ IgA complex through the oral epithelium, oropharynx bidirectional, from apical membranes to the basolateral and vice versa [140]. This EBV transmigration potentially contributes to initial EBV penetration into B-cells that starts the systemic infection. EBV secretion may occur into saliva in EBV-infected individuals [114, 141]. However, EBV could not be detected in oropharyngeal in the primary stage of infection in the process of transcytosis [142].

5.2. EBV Has High Tropism for B Lymphocytes. EBV interacts with naive or memory B lymphocytes in Waldeyer’s ring. Waldeyer’s ring is situated in lymphoid tissue and surrounds the oropharynx [143]. EBV have a high affinity for the B-cell and complement receptor type 2 (CR2) or CD21 present on the surface of B-cell facilitate the attachment of EBV envelope glycoprotein gp350/220 to B-cell [144, 145]. Following attachment, internalization of EBV occurs in the cells via the endocytosis. Further, this fusion of EBV envelopes proteins and B-cells triggers interaction of another envelopes glycoproteins, that is, gp42. Gp42 interact with HLA class II which is present on B-cells and make a core fusion complex gh/gL/gp42 and further make internalization process [146, 147].

Fate of EBV-infected B-cells depends on their niche as these cells may initiate proliferation or they can reach the memory compartment. EBV establishes a latency and expresses some limited sets of genes if B-cells reach memory compartment [144, 145]. B-cell infection mostly causes latency (I, II, III) [86, 148]; however, freshly isolated B-cells from an EBV-infected tumor lead to transformation and reactivation in vitro [149, 150]. In vivo study suggested that EBV-infected B-cells cause infectious mononucleosis with an incubation period of 30–50 days [81, 121]. Several studies suggested that it is difficult to determine EBV DNA in epithelial cells during primary infection. It is debatable how epithelial cells spread the virus to precede infection of B lymphocytes. Moreover, later EBV-related severe disease shows virus amplification in epithelial cells before shedding in saliva which at least gives some evidential support as virus shed almost daily in the saliva of carriers has the glycoprotein composition of the virus made in an epithelial cell rather than a B-cells [122, 151].

Infected B-cells reach the circulation, and some B-cells may also go to transformation [152, 153]. Cytotoxic T lymphocytes response occurs for the B-cells and mostly this process is due to latent B-cells infection. However, terminal differentiation of B cell occurs through immune response [154]. Infected memory B-cells may reach the site of immune response and further divide into plasma and memory cells. This process initiates reactivation of EBV into lytic cycle in B-cells and this causes more infection to noninfected B-cells and hence replenishes EBV-infected B-cells latent reservoir. This establishes a cycle of persistence in the life of a healthy carrier [155–158]. It is assumed that lytic release of the virus has a high tropism to epithelial cells than B-cells [159]. In vitro studies suggested that EBV loaded B-cells or B-cells fragments have a high rate of infectivity to epithelial cells [160, 161].

5.3. Lytic Release of EBV from B-Cells Has a High Tropism to Infect Other Epithelial Cells. Terminal differentiation of infected memory cells triggers EBV lytic replication [154]. This can occur in any parts/organisms of the host where the infected memory cells travel and EBV spread through cell to cell contact [162, 163]. A study suggested that undifferentiated basal epithelial cells support latent EBV infection, while differentiation of epithelial cells promotes lytic reactivation [157]. A direct coculture experiment of epithelial cells with EBV-producing Akaka cells shows that cell-cell contact is required for the EBV entry to epithelial cells. An increase of infection efficiency was observed up to 1,000 times as compared to the only viral supernatant harvested from EBV-producing cells [158, 160]. In vitro experiment suggested that complement receptor 2 (CR2) was not behind the epithelium infection for EBV, as CR2 expression was not detected in most of the infected epithelial cells [164]. Hence, it is thought to be triggered by binding of epithelial cells integrins αv6 or αv8 to viral glycoproteins gH/gL [165]. However, these integrins receptors present on epithelial cells show a week affinity with EBV compared to CR2, and hence a cell to cell contact is necessary for the attachment of the receptors of virus released from B-cells to the epithelial cells [158, 160].

Another study of the coinfection suggested that CD21 receptor on epithelial cells plays an important role in infecting epithelial cells from EBV-producing B-cells. EBV induces a strong adhesion between B-cells and epithelial cells through activation of CD21 [166]. In a coculture experiment of EBV infected B-cells prelabelled with mAb to its cell surface and epithelial cells shows interaction of EBV glycoprotein gp350 with the CD21 complex members, CD21, CD81, and CD19, between B-cell and epithelial cell synapse [166]. Members of tetraspanins, CD82 and CD63, members of integrin’s family LFA-1, integrin β1, CD11b, and integrin αvβ6, and members of Ig superfamily ICAM-1 and CD48 also show interaction of EBV glycoproteins and CD21 [166]. Virus genome integrates into host epithelial cell genome and amplifies with it [162]. EBV establishes a cycle of persistence in a healthy human and starts to be released in saliva or infects more B-cells. Thus, EBV spread throughout the superbasal epithelium and express latent as well as lytic proteins (Figure 2) [163, 167].

6. Helicobacter pylori Infection in Epithelial Cells

H. pylori infection spreads from contaminated food or may also be transferred from faces to the mouth [70]. The bacteria neutralize stomach acids and cause gastric ulcer when they penetrate the gastric mucous lining [168]. Two types of H. pylori may be found in the gastric or mucosal lining: coccoid type and helical type [169, 170]. Helical type of H. pylori
Figure 2: Mechanisms of EBV and H. pylori coinfection in gastric epithelial cells. A detailed illustrative mechanism demonstrated in gastric epithelial cells. H. pylori infection leads to oxidative stress, toxin, and necrosis in cells. These reactions further lead to chronic inflammation, epigenetic modification, and mutation. All these alterations led to genomic instability. EBV infection leads to the expression of lytic and latent genes of EBV. These viral genes regulated epigenetic modification and chronic inflammation. Further these EBV derived mechanisms lead to genomic instability. Finally, genomic instability is one of the potent sources of carcinogenesis.

may be transformed into coccoid type. Coccoid type is less vulnerable with low antigenicity and less vulnerable in gastric lining with low production of cytotoxic protein products (CagA), arginase RocF, tumor necrosis factor-α (TNF-α), and others [171]. This makes H. pylori escape from immune response more easily [169, 170, 172, 173]. Nearly, 20% of H. pylori in the stomach lining adhere to the epithelial cells surface while the rest are attached through the cell to cell junction. Few numbers of H. pylori bacteria are also found in deeper intercellular space [174]. Autotransporter proteins present on H. pylori surface, BabA, SabA, AlpA, AlpB, HopZ, OipA, and others, facilitate the adherence to the epithelial surface [174–181]; however, no individual protein is found essential [182, 183]. Additionally, differential expression of these proteins occurs between strains as well as within a single strain. Thus, over time, H. pylori acquire a dynamic adaptation by alteration in gene expression, inactivation, or recombination (Figure 2) [184, 185].

7. Methylation

7.1. EBV and Methylation. Promoter region hypermethylation in certain genes is frequently seen in EBV-positive GC compared to EBV-negative GC [16, 186]. GC and other most
common cancers occur by the genetic and epigenetic changes over an extended period. Methylation is common in cancer and can be divided into two categories, complete genome hypomethylation which causes cancer due to genetic reason [187, 188] and regional hypermethylation that are mostly caused by infection or long-term inflammation [187, 189, 190]. Host cellular machinery plays a more important role and induces aberrant methylation than viral factors [188, 191]. Host cells initiate dense methylation to silence EBV genes but in this process host genes themselves become extensively methylated [192, 193]. H. pylori are considered as major factors of GC, and aberrant methylation is also the hallmark of H. pylori-related GC [194]. Hypermethylation has been linked to H. pylori-related gastritis and inflammation [195]. The mechanisms of H. pylori induced hypermethylation are unknown and it is also thought that there is possible involvement of ROS/NOS [196]. Though several studies suggest an association of EBV and H. pylori coinfection in the occurrence of GC, the mechanism is still unclear [78, 197, 198]. A recently published data in AGS cell line demonstrated that EBV also methylated those host genes which are associated with neutralized CagA toxin of H. pylori [199]. Another study suggests that cooperation of EBV gene Zta with H. pylori has some positive link to GC [79].

In a study in cancer-related signalling pathways in EBV-associated GC, genes of cell cycle regulation (IGFBP3, CDKN2A, ID2, HSP70, CCND1, and ID4), DNA repair (BRCA1, TFF1), cell adhesion (ICAM1), angiogenesis (HIF1A), and inflammation (COX2) were found deregulated [200]. EBV-specific patterns were observed in CpG island DNA methylation and demethylation for some promoter sequence [201, 202]. The loss of 3 critical tumor suppressor genes, CDH1 (E-cadherin) [198], p73 [203], and CDKN2A (p16) [201], in EBV-associated GC is also seen. EBV-specific CpG island methylation and demethylation were observed by bisulfite DNA sequencing [202]. However, EBV is associated with epigenetic changes of apoptosis (APK, BNIP3, FAM3B HRK, IL15RA, MINT31, p16, p73, PTEN, and RASSF1A), cell cycle regulation (APC, p15, p16, p57, and p73), cell proliferation (E-Cadherin, HRASLS, IL15RA, MINT31, NKKX3.1, RUNX3, TIMP2, and TIMP3), cell signalling (14-3-3 Sigma, CSPG2, MINT1, MINT2, and PLXND1), cell adhesion (EPHB6, FLNC, FSD, REC8, and CSPG2), migration (EPHB6), and many other epigenetic changes (BCL7A, BLU, CHFR, CXXC4, GSTP1, HLTF, HOXA10, IHH, MARKI, MINT25, PAX-β, SCARF2, STRI, THBD, and WNT5A) [17, 40, 190, 191, 204–211]. Associations of EBV factors with different host machinery and methylation are listed in Tables 2 and 3.

Aberrant DNA methylations are catalyzed by the enzymes, namely, DNA methyltransferases (DNMTs) [54]. DNTM1, DNMT3A, and DNMT3B are isofoms of DNMTs which maintain the original methylation patterns after replication and target unmethylated CpG islands to initiate methylation [55]. Overexpression of these 3 isofoms was observed in H. pylori-related GC [56]. It was reported that CDH1 gene methylation was higher in H. pylori associated gastric mucosa than in H. pylori negative gastric mucosa [57, 212]. CDH1 is a cell-cell adhesion glycoprotein, which is frequently inactivated in GC. In H. pylori induced gastritis, COX2 [213], IL1-β [214], IFN-γ [215], TNF-α [216], NOs 2 [217], and genes associated with the inflammation were found to be highly upregulated [218]. A study suggested upregulation of SMARC1 protein through miR-190-3p in H. pylori associated GC. Further, overexpression of this

---

**Table 2**

| EBV gene          | Cellular response                  | Reference |
|-------------------|------------------------------------|-----------|
| EBNA, BALF1, EBERs, BARTs | Tumor growth and metastasis      | [36–38]  |
| LMP1, EBNA        | Angiogenesis                       | [38, 39]  |
| LMP1, BARTs       | Invasion, metastasis               | [36, 40]  |
| BARTs, EBNA, LMPs | ECM remodelling                     | [39, 41, 42] |
| EBNA, LMPs, EBERs, BARTs | Cell migration                  | [43–45]  |
| EBNA, LMPs, Zta, BARTs | Stemness                         | [41, 42]  |

EBNAs: Epstein-Barr nuclear antigens, BALF1: LMP1: latent membrane protein 1, EBERs: Epstein-Barr virus-encoded small RNAs, BARTs: Bam HI A rightward transcripts, LMPs: latent membrane proteins, and Zta: protein encoded by BZLF1.

**Table 3**

| EBV gene | Host gene interaction | Reference |
|----------|-----------------------|-----------|
| LMP1     | CDH1                  | [42, 43]  |
| LMP2A    | PTEN, STAT3           | [46–48]  |
| EBERs    | IGF-I                 | [49, 50]  |
| LMP1, LMP2A | DNMT1, DNMT3b          | [51, 52]  |
| BARF1    | Cyclin D, NfkB        | [49, 53]  |
| Zta      | Acetyl-transferase protein CBP, EGR1 | [54–57]  |

LMP: latent membrane protein, EBERs: Epstein-Barr virus-encoded small RNAs, BARF1: Bam HI A rightward frame 1, CDH1: Cadherin 1, PTEN: phosphatase and tensin homolog, IGF1: insulin-like growth factor 1, DNMT1: DNA methyltransferase 1, DNMT3b: DNA methyltransferase 3b, and EGR 1: early growth response gene 1.
protein causes oncogenic phenotype expression in in vitro and in vivo studies [219]. In another study, downregulation of Gastrokine (GKN1) was observed in H. pylori associated GC. GKN1 facilitates the restoration and proliferation after gastric epithelial injury and suppresses GC. This study also revealed that GKN1 inversely correlated the expression of DNMT1 and EZH2 (enhancer of zeste homologue 2) [220]. EZH2 is a potential target of many types of cancers [221]. Another study suggested that deregulation of Forkhead box protein (FOX) and methylation was observed in H. pylori associated GC. Also, dysregulation of FOXD3 promotes gastric carcinogenesis [222]. Many other genes found upregulated by H. pylori are associated with cell cycle progression and proliferation (p14, p16, p21, p27, RAB40C, COX 2, FOS, ERBB2, FGFR2, ABL1, ECOP, JAK2, MYC, MET, SIRT1, PDCD4, TRAF6, GMNN, and CCNE2) [213, 223–242], apoptosis (RECK, SMAD4, TRAIL, MCL1, BIM, XIAP, and PDKI) [243–250], and invasion and metastasis (PTEN, WNT 5a, EDNRA, ROR2, EPB41L3, MMP1, MMP10, HMGA2, ROBO1, TGF-β, EZH2, casein kinase 2, and ZEB) [251–262]. Several studies showed that the upregulation of inflammatory cytokines III-β, NO 2, and TNF-α induced methylation [46–49, 51, 52, 263]. H. pylori induces oxidative stress, ROS, and RNS which can cause p53 point mutations [264–267]. Nitric oxide (NO) can cause G:T mismatch during DNA synthesis and eventually results in G:C to A:T base transversion and epigenetic modification of tumorigenic genes (Figure 2) [268, 269].

8. EBV and H. pylori Factors Contributing to the Development of GC

Interaction between EBV and H. pylori in host stomach lining may have some synergistic effects in the development of GC. Many genes were found methylated in EBV and H. pylori coinfected gastric adenocarcinomas. Most frequently hypermethylated genes include COX 2, DAPK, CDH1, CDKN2A, and hMLH1. These genes are commonly found altered in various cancer types including GC [270]. Further, H. pylori positive individuals show a significantly higher EBV DNA load which suggests H. pylori role in lytic phase conversion of EBV [271]. Also, EBV DNA load was more in H. pylori positive patients than those uninfected with GC [272]. Another study on coinfection suggests that EBV with H. pylori induces severe inflammatory responses in the individual and, hence, increases the risk of developing the intestinal type GC [78]. It is thought that there are two possible mechanisms, first an additional inflammatory response in coinfection and increased tissue damaging by both H. pylori and EBV [79, 215]. In this scenario, significant elevation was observed in IL-1β [273], TNF-α [274], and IL-8 [275]. A study in pediatrics patients demonstrated that H. pylori infection was not but the presence of EBV, an essential factor for severe inflammation [79]. The second mechanism is based on gene products interaction which is more significant between EBV and H. pylori. In vitro study found that EBV reactivation occurs by the PLCγ signalling pathway and H. pylori toxin CagA strongly activates PLCγ [237] and also activates several kinases [276]. An ectopic expression on transgenic mice supports the oncoprotein nature of CagA [277–280]. CagA of H. pylori and LMP1 and LMP2 of EBV activate NF-κB and MAP kinases, which are well-known pathways of cell survival and proliferation during carcinogenesis [211, 281]. H. pylori associated oncoprotein CagA triggers an aberrant activation of WNT signalling pathway [282]. WNT signalling pathway activation leads to the activation of CDX1, a downstream gene [283], which reprograms epithelial cells in mucosal lining to acquire stemness properties by inducing SALL4 and KLF5 factors [284]. Another study also suggests that EBV and H. pylori transform the stomach epithelium cells and play roles in carcinogenesis [78]. Both pathogens induce common pathways which leads to the activation of transforming factors in stomach epithelial cells by β-catenin/TCF-4 signalling pathway [79, 285]. In another study, an association between EBV and H. pylori copositivity was shown and significant infiltration in premalignant lesions in GC was observed [78]. A study by Szkardakiewicz et al. suggested that Bcl2 expression was higher in EBV and H. pylori associated GC; thus, excessive overexpression may be the result of coinfection [286]. Several studies also revealed that PCDH10 (protocadherin 10) is calcium dependent cell adhesion molecule which suppresses tumor in gastric epithelial hypermethylated in H. pylori associated GC and EBV-infected individual [287–289]. SWI/SNF remodelling complex which is commonly observed in GC is found associated with both pathogens, EBV and H. pylori [290].

A recent study suggested that host protein SHP 1 interacts with H. pylori CagA protein and dephosphorylates CagA, thus preventing oncogenic activity of CagA. However, EBV coinfection causes methylation of host SHP 1 and prevents its dephosphorylation activity of CagA and thus may increase oncogenic potential of CagA [199]. Further, a study suggested that both EBV and H. pylori coinfection were ominously more dominant in intestinal ulcer patients compared to GERD and dyspepsia patients [291]. H. pylori positive patients show increased anti-EBV lgG titre which suggests H. pylori role in augmenting EBV DNA load and higher immune responses [291]. However, some study is also available which suggested that H. pylori attenuated TGF-β expression which reactivates EBV lytic phase and might play a role in preventing EBV lytic reactivation and preventing GC [292]. Therefore, the mechanism of coexistence for H. pylori and EBV must be studied to find the probable and potential pathogenic roles for both pathogens.

9. Future Direction

To date, mostly clinical findings explicitly described the EBV and H. pylori coinfection in GC. Moreover, how these pathogens target host factors and downstream pathways is still unexplored. Therefore, a detailed study which could potentially uncover the mechanism of EBV and H. pylori in the progression of GC could be interesting to peruse. How H. pylori antigens interacted with EBV antigens could be interesting to explore and helps in the understanding of progression of aggressive GC. Why only few cells from host are targeted by H. pylori and EBV is also critical to understand.
Competing Interests
The authors declare that they have no competing interests.

References
[1] J. Ferlay, I. Soerjomataram, R. Dikshit et al., “Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012,” International Journal of Cancer, vol. 136, no. 5, pp. E359–E386, 2015.
[2] C. Fitzmaurice, D. Dicker, A. Pain et al., “The global burden of cancer 2013,” JAMA Oncology, vol. 1, pp. 505–527, 2015.
[3] American Cancer Society Cancer Facts & Figures 2016, Cancer Facts Fig. 2016, 1–9, 2016.
[4] R. J. L. F. Looffeld, I. Willems, J. A. Flendrig, and I. W. Arends, “Helicobacter pylori and gastric carcinoma,” Histopathology, vol. 17, no. 6, pp. 537–541, 1990.
[5] J. Parsonnet, G. D. Friedman, D. P. Vandersteen et al., “Helicobacter pylori infection and the risk of gastric carcinoma,” The New England Journal of Medicine, vol. 325, no. 16, pp. 1127–1131, 1991.
[6] E. L. Wrobleski, R. M. Jr. Peek, and K. T. Wilson, “Helicobacter pylori and gastric cancer: factors that modulate disease risk,” Clinical Microbiology Reviews, vol. 23, no. 4, pp. 713–739, 2010.
[7] S. Ishaq and L. Nunn, “Helicobacter pylori and gastric cancer: a state of the art review,” Gastroenterology and Hepatology from Bed to Bench, vol. 8, pp. 56–514, 2015.
[8] A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman, “Global cancer statistics,” CA Cancer Journal for Clinicians, vol. 61, no. 2, pp. 69–90, 2011.
[9] G. Carrasco and A. H. Corvalan, “Helicobacter pylori-induced chronic gastritis and assessing risks for gastric cancer,” Gastroenterology Research and Practice, vol. 2013, Article ID 393015, 8 pages, 2013.
[10] V. Conteduca, D. Sansonno, G. Lauletta, S. Russi, G. Ingvarallo, and F. Dammacco, “‘H. pylori infection and gastric cancer: state of the art (Review),’ International Journal of Oncology, vol. 42, no. 1, pp. 5–18, 2013.
[11] S. Hansen, K. K. Melby, S. Aase, E. Jellum, and S. E. Vollset, “Helicobacter pylori infection and risk of cardiac cancer and non-cardia gastric cancer: A Nested Case-control Study,” Scandinavian Journal of Gastroenterology, vol. 34, no. 4, pp. 353–360, 1999.
[12] M. Plummer, S. Franceschi, J. Vignat, D. Forman, and C. De Martel, “Global burden of gastric cancer attributable to Helicobacter pylori,” International Journal of Cancer, vol. 136, no. 2, pp. 487–490, 2015.
[13] IARC, Schistosomes, Liver Flukes and Helicobacter pylori, IARC, Lyon, France, 1994.
[14] G. Murphy, R. Pfeiffer, M. C. Camargo, and C. S. Rabkin, “Meta-analysis Shows that prevalence of Epstein-Barr virus-positive gastric cancer differs based on sex and anatomic location,” Gastroenterology, vol. 137, no. 3, pp. 824–833, 2009.
[15] D. Shibata and L. M. Weiss, “Epstein-Barr virus-associated gastric adenocarcinoma,” American Journal of Pathology, vol. 140, no. 4, pp. 769–774, 1992.
[16] H. Abe, A. Kaneda, and M. Fukayama, “Epstein-Barr virus-associated gastric carcinoma: use of host cell machineries and somatic gene mutations,” Pathobiology, vol. 82, no. 5, pp. 212–213, 2015.
[17] A. Shinozaki-Ushiku, A. Kunita, and M. Fukayama, “Update on epstein-barr virus and gastric cancer (review),” International Journal of Oncology, vol. 46, no. 4, pp. 1421–1434, 2015.
[18] M. Fukayama, Y. Hayashi, Y. Iwasaki et al., “Epstein-Barr virus-associated gastric carcinoma and Epstein-Barr virus infection of the stomach,” Laboratory Investigation, vol. 71, no. 1, pp. 73–81, 1994.
[19] V. Simko, N. Anand, and E. Ginter, “Gastric intestinal metaplasia—age, ethnicity and surveillance for gastric cancer,” Bratislava Medical Journal, vol. 116, no. 1, pp. 3–8, 2015.
[20] M. C. Camargo, Y. Goto, J. Zabaleta, D. R. Morgan, P. Correa, and C. S. Rabkin, “Sex hormones, hormonal interventions, and gastric cancer risk: a meta-analysis,” Cancer Epidemiology Biomarkers and Prevention, vol. 21, pp. 20–38, 2012.
[21] P. Sipponen, M. Kekki, and M. Siurala, “Increased risk of gastric cancer in males affects the intestinal type of cancer and is independent of age, location of the tumour and atrophic gastritis,” British Journal of Cancer, vol. 57, no. 3, pp. 332–336, 1988.
[22] Z. Zhang and X. Zhang, “Salt taste preference, sodium intake and gastric cancer in China,” Asian Pacific Journal of Cancer Prevention, vol. 12, no. 5, pp. 1207–1210, 2011.
[23] B. Peleteiro, C. Lopes, C. Figueredo, and N. Lunet, “Salt intake and gastric cancer risk according to Helicobacter pylori infection, smoking, tumour site and histological type,” British Journal of Cancer, vol. 104, no. 1, pp. 198–207, 2011.
[24] S. Tsugane, S. Sasazuki, M. Kobayashi, and S. Sasaki, “Salt and salted food intake and subsequent risk of gastric cancer among middle-aged Japanese men and women,” British Journal of Cancer, vol. 90, no. 1, pp. 128–134, 2004.
[25] B. Peleteiro, C. Castro, S. Morais, A. Ferro, and N. Lunet, “Worldwide burden of gastric cancer attributable to tobacco smoking in 2012 and predictions for 2020,” Digestive Diseases and Sciences, vol. 60, no. 8, pp. 2470–2476, 2015.
[26] A. M. Y. Nomura, L. R. Wilkens, B. E. Henderson, M. Epplein, and L. N. Kolonel, “The association of cigarette smoking with gastric cancer: The Multiethnic Cohort Study,” Cancer Causes and Control, vol. 23, no. 1, pp. 51–58, 2012.
[27] S.-H. Ma, W. Jung, E. Weiderpass et al., “Impact of alcohol drinking on gastric cancer development according to Helicobacter pylori infection status,” British Journal of Cancer, vol. 113, no. 9, pp. 1381–1388, 2015.
[28] B. Balachandran and V. M. Sivaramkrishnan, “Induction of tumours by Indian dietary constituents,” Indian Journal of Cancer, vol. 32, no. 3, pp. 104–109, 1995.
[29] K. Lazarevic, A. Nagorni, N. Rancic, S. Milutinovic, L. Stosic, and I. Ilijev, “Dietary factors and gastric cancer risk: hospital-based case control study,” Journal of B.U.ON., vol. 15, no. 1, pp. 89–93, 2010.
[30] A. Pandey, S. C. Tripathi, S. Mahata et al., “Carcinogenic Helicobacter pylori in gastric pre-cancer and cancer lesions: association with tobacco-chewing,” World Journal of Gastroenterology, vol. 20, no. 22, pp. 6860–6868, 2014.
[31] T. Boysen, J. Friborg, K. Stribolt et al., “Epstein-Barr virus-associated gastric carcinoma among patients with pernicious anemia,” International Journal of Cancer, vol. 129, no. 11, pp. 2756–2760, 2011.
[32] G. Murphy, S. M. Dawsey, E. A. Engels et al., “Cancer risk after pernicious anemia in the US elderly population,” Clinical Gastroenterology and Hepatology, vol. 13, no. 13, pp. 2282–2289.e4, 2015.
L. Vannella, E. Lahner, J. Osborn, and B. Annibale, “Systematic review: gastric cancer incidence in pernicious anaemia,” *Alimentary Pharmacology and Therapeutics*, vol. 37, no. 4, pp. 375–382, 2013.

J. Lagergren, A. Lindam, and R. M. Mason, “Gastric stumps cancer after distal gastrectomy for benign gastric ulcer in a population-based study,” *International Journal of Cancer*, vol. 131, no. 6, pp. E1048–E1052, 2012.

M. Yaghoobi, R. Bijarchi, and S. A. Narod, “Family history and the risk of gastric cancer,” *British Journal of Cancer*, vol. 102, no. 2, pp. 237–242, 2010.

K. Taniuchi, K. Yokotani, and T. Saibara, “BART inhibits pancreatic cancer cell invasion by Rac1 inactivation through direct binding to active Rac1,” *Neoplasia*, vol. 14, no. 5, pp. 440–450, 2012.

C.-F. Yang, G.-D. Yang, T.-J. Huang et al., “EB-virus latent membrane protein 1 potentiates the stemness of nasopharyngeal carcinoma via preferential activation of PI3K/AKT pathway by a positive feedback loop,” *Oncogene*, vol. 35, no. 26, pp. 3419–3431, 2016.

N. Gaur, J. Gandhi, E. S. Robertson, S. C. Verma, and R. Kaul, “Epstein–Barr virus latent antigens EBNAC3 and EBNA1 modulate epithelial to mesenchymal transition of cancer cells associated with tumor metastasis,” *Tumor Biology*, vol. 36, no. 4, pp. 3031–3060, 2015.

L.-M. Cai, X.-M. Lyu, W.-R. Luo et al., “EBV-miR-BART7-3p promotes the EMT and metastasis of nasopharyngeal carcinoma cells by suppressing the tumor suppressor PTEN,” *Oncogene*, vol. 34, no. 17, pp. 2156–2166, 2014.

A. R. Marquitz, A. Mathur, C. S. Nam, and N. Raab-Traub, “The Epstein-Barr Virus BART microRNAs target the pro-apoptotic protein Bim,” *Virology*, vol. 412, no. 2, pp. 392–400, 2011.

L. R. Wasil and K. H. Y. Shair, “Epstein-Barr virus LMP1 induces focal adhesions and epithelial cell migration through effects on integrin-α5 and N-cadherin,” *Oncogene*, vol. 4, article e171, 2015.

S. M. Krishna, J. Kattoor, and P. Balaram, “Down regulation of adhesion protein E-cadherin in Epstein-Barr virus infected nasopharyngeal carcinomas,” *Cancer Biomarkers*, vol. 1, no. 6, pp. 271–277, 2005.

S.-X. Lin, Y.-S. Zong, B. Chu et al., “Relationship between the expressions of LMP1 and E-cadherin/β-catenin in nasopharyngeal carcinoma,” *Chinese Journal of Cancer Research*, vol. 14, no. 3, pp. 202–205, 2002.

R. Hino, H. Uozaki, N. Murakami et al., “Activation of DNA methyltransferase 1 by EBV latent membrane protein 2A leads to promoter hypermethylation of PTEN gene in gastric carcinoma,” *Cancer Research*, vol. 69, no. 7, pp. 2766–2774, 2009.

X. Li and S. Bhaduri-McIntosh, “A central role for STAT3 in gammaherpesvirus-life cycle and-diseases,” *Frontiers in Microbiology*, vol. 7, article 1052, 2016.

S. Leonard, W. Wei, J. Anderton et al., “Epigenetic and transcriptional changes which follow Epstein–Barr virus infection of germinal center B cells and their relevance to the pathogenesis of Hodgkin’s lymphoma,” *Journal of Virology*, vol. 85, no. 18, pp. 9568–9577, 2011.

J. Zhao, Q. Liang, K.-F. Cheung et al., “Genome-wide identification of Epstein-Barr virus-driven promoter methylation profiles of human genes in gastric cancer cells,” *Cancer*, vol. 119, no. 2, pp. 304–312, 2013.

M. S. Chang, D. H. Kim, J. K. Roh et al., “Epstein-Barr virus-encoded BARF1 promotes proliferation of gastric carcinoma cells through regulation of NF-κB,” *Journal of Virology*, vol. 87, no. 19, pp. 10515–10523, 2013.

D. Iwakiri, T.-S. Sheen, J.-Y. Chen, D. P. Huang, and K. Takada, “Epstein-Barr virus-encoded small RNA induces insulin-like growth factor 1 and supports growth of nasopharyngeal carcinoma-derived cell lines,” *Oncogene*, vol. 24, no. 10, pp. 1767–1773, 2005.

D. Iwakiri, Y. Eizuru, M. Tokunaga, and K. Takada, “Autocrine growth of Epstein-Barr virus-positive gastric carcinoma cells mediated by an Epstein-Barr virus-encoded small RNA,” *Cancer Research*, vol. 63, no. 21, pp. 7062–7067, 2003.

H. Gruffat, E. Manetr, and A. Sergeant, “MEF2-mediated recruitment of class II HDAC at the EBV immediate early gene BZLF1 links latency and chromatin remodeling,” *EMBO Reports*, vol. 3, no. 2, pp. 141–146, 2002.

P. M. Bhende, W. T. Seaman, H.-J. Delecuse, and S. C. Kenney, “The EBV lytic switch protein, Z, preferentially binds to and activates the methylated viral genome,” *Nature Genetics*, vol. 36, no. 10, pp. 1099–1104, 2004.

J. Heather, K. Flower, S. Isaac, and A. J. Sinclair, “The Epstein-Barr virus lytic cycle activator Zta interacts with methylated ZRE in the promoter of host target gene egfr,” *Journal of General Virology*, vol. 90, no. 6, pp. 1450–1454, 2009.

M. Rodríguez-Paredes and M. Esteller, “Cancer epigenetics reaches mainstream oncology,” *Nature Medicine*, vol. 17, no. 3, pp. 330–339, 2011.

S. H. Choi, K. Heo, H.-M. Byun, W. An, W. Lu, and A. S. Yang, “Identification of preferential target sites for human DNA methyltransferases,” *Nucleic Acids Research*, vol. 39, no. 1, pp. 104–118, 2011.

H.-K. Na and J.-H. Woo, “Helicobacter pylori induces hypermethylation of CpG islands through upregulation of DNA methyltransferase: possible involvement of reactive oxygen/nitrogen species,” *Journal of Cancer Prevention*, vol. 19, pp. 259–264, 2014.

A. O.-O. Chan, S.-K. Lam, B. C.-Y. Wong et al., “Promoter methylation of E-cadherin gene in gastric mucosa associated with Helicobacter pylori infection and in gastric cancer,” *Gut*, vol. 52, no. 4, pp. 502–506, 2003.

J. S. Lim, M. J. Yun, M.-J. Kim et al., “CT and PET in stomach cancer: preoperative staging and monitoring of response to therapy,” *Radiographics*, vol. 26, no. 1, pp. 143–156, 2006.

K. Inokuchi, “Early gastric cancer viewed from its growth patterns,” *Surgery Annual*, vol. 18, pp. 113–128, 1986.

P. Correa, “Gastric cancer. Overview,” *Gastroenterology Clinics of North America*, vol. 42, no. 2, pp. 211–217, 2013.

S. G. Barreto and J. A. Windsor, “Redefining early gastric cancer,” *Surgical Endoscopy and Other Interventional Techniques*, vol. 30, no. 1, pp. 24–37, 2016.

A. R. Sepulveda, “Helicobacter, Inflammation, and Gastric Cancer,” *Current Pathobiology Reports*, vol. 1, no. 1, pp. 9–18, 2013.

D. Y. Graham, “History of Helicobacter pylori, duodenal ulcer, gastric ulcer and gastric cancer,” *World Journal of Gastroenterology*, vol. 20, no. 18, pp. 5191–5204, 2014.

J. J. Hwang, D. H. Lee, A.-R. Lee et al., “Characteristics of gastric cancer in peptic ulcer patients with Helicobacter pylori infection,” *World Journal of Gastroenterology*, vol. 21, no. 16, pp. 4954–4960, 2015.

W. Xia, X. Zhang, J. Wang, C. Sun, and L. Wu, “Survey of anaemia and Helicobacter pylori infection in adolescent girls in Suihua, China and enhancement of iron intervention effects by..."
Journal of Oncology

[100] C. Y. Ok, T. G. Papathomas, L. J. Medeiros, and K. H. Young, “EBV-positive diffuse large B-cell lymphoma of the elderly,” Blood, vol. 122, no. 3, pp. 328–330, 2013.

[101] N. Asano, S. Kato, and S. Nakamura, “Epstein-Barr virus-associated natural killer/T-cell lymphomas,” Best Practice and Research: Clinical Haematology, vol. 26, no. 1, pp. 15–21, 2013.

[102] S. A. Rezk and L. M. Weiss, “Epstein-Barr virus-associated lymphoproliferative disorders,” Human Pathology, vol. 38, no. 9, pp. 1293–1304, 2007.

[103] E. A. Chu, J. M. Wu, D. E. Tunkel, and S. L. Ishman, “Nasopharyngeal carcinoma: the role of the Epstein-Barr virus,” The Medscape Journal of Medicine, vol. 10, no. 7, article no. 165, 2008.

[104] L. S. Young and C. W. Dawson, “Epstein-Barr virus and nasopharyngeal carcinoma,” Chinese Journal of Cancer, vol. 33, no. 12, pp. 581–590, 2014.

[105] G. Murphy, R. Pfeiffer, M. C. Camargo, and C. S. Rabkin, “Meta-analysis Shows that prevalence of Epstein-Barr Virus-positive gastric cancer differs based on sex and anatomic location,” Gastroenterology, vol. 137, no. 3, pp. 824–833, 2009.

[106] A. Archimandritis, J. Bitsikas, M. Tjivras et al., “Non-cardiac gastric adenocarcinoma and Helicobacter pylori infection,” Italian Journal of Gastroenterology, vol. 25, no. 7, pp. 368–371, 1993.

[107] C. E. Taylor, “Serological techniques,” Journal of Clinical Pathology, vol. 3, no. 1, pp. 14–18, 1969.

[108] R. C. She, A. R. Wilson, and C. M. Litwin, “Evaluation of Helicobacter pylori immunoglobulin G (IgG), IgA, and IgM serologic testing compared to stool antigen testing,” Clinical and Vaccine Immunology, vol. 16, no. 8, pp. 1253–1255, 2009.

[109] P. Robertson, S. Beynon, R. Whybin et al., “Measurement of EBV-IgG anti-VCA avidity aids the early and reliable diagnosis of primary EBV infection,” Journal of Medical Virology, vol. 70, no. 4, pp. 617–623, 2003.

[110] G. Bauer, “Simplicity through complexity: immune blot with recombinant antigens as the new gold standard in Epstein-Barr virus serology,” Clinical Laboratory, vol. 47, no. 5-6, pp. 223–230, 2001.

[111] A. Crowley, J. Connell, K. Schaffer, W. Hall, and J. Hassan, “Is there diagnostic value in detection of immunoglobulin G antibodies to the Epstein-Barr virus early antigen?” BioResearch Open Access, vol. 1, pp. 291–296, 2012.

[112] M. De Paschale and P. Clerici, “Serological diagnosis of Epstein-Barr virus infection: problems and solutions,” World Journal of Virology, vol. 1, no. 1, pp. 31–43, 2012.

[113] J. S. Klutts, B. A. Ford, N. R. Perez, and A. M. Gronowski, “Evidence-based approach for interpretation of Epstein-Barr virus serological patterns,” Journal of Clinical Microbiology, vol. 47, no. 10, pp. 3204–3210, 2009.

[114] R. D. Hess, “Routine Epstein-Barr virus diagnostics from the laboratory perspective: still challenging after 35 years,” Journal of Clinical Microbiology, vol. 42, no. 8, pp. 3381–3387, 2004.

[115] B. C. Gärtner, R. D. Hess, D. Bandt et al., “Evaluation of four commercially available Epstein-Barr virus enzyme immunoassays with an immunofluorescence assay as the reference method,” Clinical and Diagnostic Laboratory Immunology, vol. 10, no. 1, pp. 78–82, 2003.

[116] I. Saito, B. Servenius, T. Compton, and R. I. Fox, “Detection of Epstein-Barr virus DNA by polymerase chain reaction in blood and tissue biopsies from patients with Sjogren’s syndrome,” Journal of Experimental Medicine, vol. 169, no. 6, pp. 2191–2198, 1989.

[117] M. De Paschale and P. Clerici, “Serological diagnosis of Epstein-Barr virus infection: problems and solutions,” World Journal of Virology, vol. 1, pp. 31–43, 2012.

[118] C. Gartzonikaa, G. Vrionib, E. Priavalia, G. Pappasc, and S. Levidiotoua, “Utility of real-time PCR in the diagnosis of primary Epstein-Barr virus infection,” Journal of Medical Microbiology & Diagnosis, vol. 2, no. 1, pp. 1–4, 2012.

[119] D. Buelow, Y. Sun, L. Tang, Z. Gu, S. Pounds, and R. Hayden, “Comparative evaluation of four real-time PCR methods for the quantitative detection of Epstein-Barr virus from whole blood specimens,” The Journal of Molecular Diagnostics, vol. 18, pp. 527–534, 2016.

[120] H. Izasa, A. Nanbo, J. Nishikawa, M. Jinushi, and H. Yoshiyama, “Epstein-barr virus (EBV)-associated gastric carcinoma,” Viruses, vol. 4, no. 12, pp. 3420–3439, 2012.

[121] H. H. Balfour Jr., C. J. Holman, K. M. Hokanson et al., “A prospective clinical study of Epstein-Barr Virus and host interactions during acute infectious mononucleosis,” Journal of Infectious Diseases, vol. 192, no. 9, pp. 1505–1512, 2005.

[122] H. Hjalgrim, F. Friborg, and M. Melbye, The Epidemiology of EBV and Its Association with Malignant Disease, Cambridge University Press, 2007.

[123] R. Hassan, L. R. White, C. G. Stefanoff et al., “Epstein-Barr Virus (EBV) detection and typing by PCR: a contribution to diagnostic screening of EBV-positive Burkitt’s lymphoma,” Diagnostic Pathology, vol. 1, no. 1, article no. 17, 2006.

[124] H. Kimura, M. Morita, Y. Yabuta et al., “Quantitative analysis of Epstein-Barr Virus virus load by using a real-time PCR assay,” Journal of Clinical Microbiology, vol. 37, no. 1, pp. 132–136, 1999.

[125] M. Mifahussurur and Y. Yamaoka, “Diagnostic methods of Helicobacter pylori infection for epidemiological studies: critical importance of indirect test validation,” BioMed Research International, vol. 2016, Article ID 4819423, 14 pages, 2016.

[126] C. Burucoa, J.-C. Delchier, A. Courillon-Mallet et al., “Comparative evaluation of 29 commercial Helicobacter pylori serological kits,” Helicobacter, vol. 18, no. 3, pp. 169–179, 2013.

[127] Y.-K. Wang, F.-C. Kuo, C.-J. Liu et al., “Diagnosis of helicobacter pylori infection: current options and developments,” World Journal of Gastroenterology, vol. 21, no. 40, pp. 11221–11235, 2015.

[128] M. H. Wilcox, T. H. S. Dent, J. O. Hunter et al., “Accuracy of serology for the diagnosis of Helicobacter pylori infection—a comparison of eight kits,” Journal of Clinical Pathology, vol. 49, no. 5, pp. 373–376, 1996.

[129] R. C. She, A. R. Wilson, and C. M. Litwin, “Evaluation of Helicobacter pylori immunoglobulin G (IgG), IgA, and IgM serologic testing compared to stool antigen testing,” Clinical and Vaccine Immunology, vol. 16, no. 8, pp. 1253–1255, 2009.

[130] A. Kindermann, N. Konstantopoulos, N. Lehn, H. Demmelmaier, and S. Koletzko, “Evaluation of two commercial enzyme immunoassays, testing immunoglobulin G (IgG) and IgA responses, for diagnosis of Helicobacter priori infection in children,” Journal of Clinical Microbiology, vol. 39, no. 10, pp. 3591–3596, 2001.

[131] M. Ferwana, I. Abdulmajeed, A. Alhajiahmed et al., “Accuracy of urea breath test in Helicobacter pylori infection: meta-analysis,” World Journal of Gastroenterology, vol. 21, no. 4, pp. 1305–1314, 2015.

[132] L. Masucci, G. Blackhouse, and R. Goeree, “Cost-effectiveness of the carbon-13 urea breath test for the detection of Helicobacter pylori: an economic analysis,” Ontario Health Technology Assessment Series, vol. 13, no. 20, pp. 1–28, 2013.
G. J. Babcock, L. L. Decker, R. B. Freeman, and D. A. Thorley-Lawson, “Epstein-Barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients,” *Journal of Experimental Medicine*, vol. 190, no. 4, pp. 567–576, 1999.

I. S. Tracy, K. Kakalacheva, J. D. Lünenmann, K. Luzuriaga, J. Middeldorp, and D. A. Thorley-Lawson, “Persistence of Epstein-Barr virus in self-reactive memory B cells,” *Journal of Virology*, vol. 86, no. 22, pp. 12330–12340, 2012.

G. Szakonyi, M. G. Klein, J. P. Hannon et al., “Structure of the Epstein-Barr virus major envelope glycoprotein,” *Nature Structural and Molecular Biology*, vol. 13, no. 11, pp. 996–1001, 2006.

L. M. Hutt-Fletcher, “Epstein-Barr virus entry,” *Journal of Virology*, vol. 81, no. 15, pp. 7825–7832, 2007.

E. A. Hurley and D. A. Thorley-Lawson, “B cell activation and the establishment of Epstein-Barr virus latency,” *Journal of Experimental Medicine*, vol. 168, no. 6, pp. 2059–2075, 1988.

M. Dorner, F. Zucol, C. Berger et al., “Distinct ex vivo susceptibility of B-cell subsets to Epstein-Barr virus infection according to differentiation status and tissue origin,” *Journal of Virology*, vol. 82, no. 9, pp. 4400–4412, 2008.

A. B. Rickinson, D. J. Moss, D. J. Allen, L. E. Wallace, M. Rowe, and M. A. Epstein, “Reactivation of Epstein-Barr virus-specific cytotoxic T cells by in vitro stimulation with the autologous lymphoblastoid cell line,” *International Journal of Cancer*, vol. 27, no. 5, pp. 593–601, 1981.

G. T. Huynh and L. Rong, “ Modeling the dynamics of virus shedding into the saliva of Epstein-Barr virus positive individuals,” *Journal of Theoretical Biology*, vol. 310, pp. 105–114, 2012.

J. H. Pope, W. Scott, and D. J. Moss, “Human lymphoid cell transformation by Epstein-Barr virus,” *Nature New Biology*, vol. 246, no. 153, pp. 140–141, 1973.

A. M. Price and M. A. Luftig, “Dynamic epstein-barr virus gene expression on the path to B-cell transformation,” *Advances in Virus Research*, vol. 88, pp. 279–313, 2014.

L. L. Laichalk and D. A. Thorley-Lawson, “Terminal differentiation into plasma cells initiates the replicative cycle of Epstein-Barr virus in vivo,” *Journal of Virology*, vol. 79, no. 2, pp. 1296–1307, 2005.

A. Nanbo, H. Terada, K. Kachi, K. Takada, and T. Matsuda, “Roles of cell signaling pathways in cell-to-cell contact-mediated Epstein-Barr virus transmission,” *Journal of Virology*, vol. 86, no. 17, pp. 9285–9296, 2012.

S. C. Kenney, *Reactivation and Lytic Replication of EBV*, Cambridge University Press, Cambridge, UK, 2007.

D. M. Nawandar, A. Wang, K. Makielski et al., “Differentiation-dependent KLF4 expression promotes lytic Epstein-Barr virus infection in epithelial cells,” *PLoS Pathogens*, vol. 11, no. 10, Article ID e1005195, 2015.

S. Imai, J. Nishikawa, and K. Takada, “Cell-to-cell contact as an efficient mode of Epstein-Barr virus infection of diverse human epithelial cells,” *Journal of Virology*, vol. 72, no. 5, pp. 4371–4378, 1998.

R. Feederle, B. Neuhielr, H. Bannert, K. Geletneky, C. Shannon-Lowe, and H.-J. Delecluse, “Epstein-Barr virus B95.8 produced in 293 cells shows markedly tropism for differentiated primary epithelial cells and reveals interindividual variation in susceptibility to viral infection,” *International Journal of Cancer*, vol. 121, no. 3, pp. 588–594, 2007.

C. Ni, Y. Chen, M. Zeng et al., “In-cell infection: a novel pathway for Epstein-Barr virus infection mediated by cell-in-cell structures,” *Cell Research*, vol. 25, no. 7, pp. 785–800, 2015.

C. D. Shannon-Lowe, B. Neuhielr, G. Baldwin, A. B. Rickinson, and H.-J. Delecluse, “Resting B cells as a transfer vehicle for Epstein-Barr virus infection of epithelial cells,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 103, no. 18, pp. 7065–7070, 2006.

C. Shannon-Lowe, E. Adland, A. I. Bell, H.-J. Delecluse, A. B. Rickinson, and M. Rowe, “Features distinguishing Epstein-Barr virus infections of epithelial cells and B cells: viral genome expression, genome maintenance, and genome amplification,” *Journal of Virology*, vol. 83, no. 15, pp. 7749–7760, 2009.

L. M. Hutt-Fletcher, “Epstein-Barr virus replicating in epithelial cells,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 111, no. 46, pp. 16242–16243, 2014.

H. Yoshiyama, S. Imai, N. Shimizu, and K. Takada, “Epstein-Barr virus infection of human gastric carcinoma cells: implication of the existence of a new virus receptor different from CD21,” *Journal of Virology*, vol. 71, no. 7, pp. 5688–5691, 1997.

L. S. Chesnokova, S. L. Nishimura, L. M. Hutt, and L. M. Hutt-Fletcher, “Fusion of epithelial cells by Epstein–Barr virus proteins is triggered by binding of viral glycoproteins gHgL to integrins avβ6 or avβ8,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 106, no. 48, pp. 20464–20469, 2009.
C. Shannon-Lowe and M. Rowe, "Epstein-Barr virus infection of polarized epithelial cells Via the basolateral surface by memory b cell-mediated transfer infection," *PLoS Pathogens*, vol. 7, no. 5, Article ID e1001338, 2011.

R. M. Temple, J. Zhu, L. Budgeon, N. D. Christensen, C. Meyers, and C. E. Sample, "Efficient replication of Epstein-Barr virus in stratified epithelium in vitro," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 111, no. 46, pp. 16544–16549, 2014.

A. Berger, "Scientists discover how helicobacter survives gastric acid," *BMJ*, vol. 320, 2000.

X. Wang, E. Sturegård, R. Rupar et al., "Infection of BALB/c A mice by spiral and coccoid forms of *Helicobacter pylori*," *Journal of Medical Microbiology*, vol. 46, no. 8, pp. 657–663, 1997.

N. Saito, H.-K. Ooi, K. Konishi, E. Shoji, M. Kato, and M. X. Masahiro Asaka, "Coccoid *Helicobacter pylori* can directly adhere and invade in agminated formation to human gastric epithelial cells," *Advances in Microbiology*, vol. 2, no. 2, pp. 112–116, 2012.

S. B. Yoon, J. M. Park, J.-Y. Lee et al., "Long-term pretreatment with proton pump inhibitor and Helicobacter pylori eradication rates," *World Journal of Gastroenterology*, vol. 20, no. 4, pp. 1061–1066, 2014.

N. F. Azevedo, C. Almeida, L. Cerqueira, S. Dias, C. W. Keevil, and M. J. Vieira, "Coccoid form of Helicobacter pylori as a morphological manifestation of cell adaptation to the environment," *Applied and Environmental Microbiology*, vol. 73, no. 10, pp. 3423–3427, 2007.

M. F. Loke, C. G. Ng, Y. Vilashni, J. Lim, and B. Ho, "Understanding the dimorphic lifestyles of human gastric pathogen *Helicobacter pylori* using the SWATH-based proteomics approach," *Scientific Reports*, vol. 6, Article ID 26784, 2016.

B. Bauer and T. F. Meyer, "The human gastric pathogen Helicobacter pylori and its association with gastric cancer and ulcer disease," *Ulcers*, vol. 2011, Article ID 340157, 23 pages, 2011.

A. Dossumbekova, C. Prinz, J. Mages et al., "*Helicobacter pylori* HopH (OipA) and bacterial pathogenicity: genetic and functional genomic analysis of hopH gene polymorphisms," *Journal of Infectious Diseases*, vol. 194, no. 10, pp. 1346–1355, 2006.

T. L. Testerman, D. J. McGee, and H. L. T. Mobley, *Adherence and Colonization*, ASM Press, Washington, DC, USA, 2001.

M. Oleastro and A. Ménard, "The role of *Helicobacter pylori* outer membrane proteins in adherence and pathogenesis," *Biology*, vol. 2, no. 3, pp. 1100–1134, 2013.

O. A. Senkovich, J. Yin, V. Ekshteyn et al., "*Helicobacter pylori* AlpA and AlpB Bind host laminin and influence gastric inflammation in gerbils," *Infection and Immunity*, vol. 79, no. 8, pp. 3106–3116, 2011.

A. Magalhães and C. A. Reis, "*Heliobacter pylori* adhesion to gastric epithelial cells is mediated by glycan receptors," *Brazilian Journal of Medical and Biological Research*, vol. 43, no. 7, pp. 611–618, 2010.

S. Talarico, S. E. Whitefield, J. Fero, R. Haas, and N. R. Salama, "Regulation of Helicobacter pylori adherence by gene conversion/inni," *Molecular Microbiology*, vol. 84, no. 6, pp. 1050–1061, 2012.

N. Ishiihama, M. Suzuki, H. Ashida et al., "BabA-mediated adherence is a potentiator of the *Helicobacter pylori* type IV secretion system activity," *Journal of Biological Chemistry*, vol. 286, no. 28, pp. 25256–25264, 2011.
[198] M. Sudo, J.-M. Chong, K. Sakuma et al., “Promoter hypermethylation of E-cadherin and its abnormal expression in Epstein-Barr virus-associated gastric carcinoma,” International Journal of Cancer, vol. 109, no. 2, pp. 194–199, 2004.

[199] P. Saju, N. Murata-Kamiya, T. Hayashi et al., “Host SHPI phosphatase antagonizes Helicobacter pylori CagA and can be downregulated by Epstein-Barr virus,” Nature Microbiology, vol. 1, Article ID 16026, 2016.

[200] J. L. Ryan, R. J. Jones, S. C. Kenney et al., “Epstein-Barr virus-specific methylation of human genes in gastric cancer cells,” Infectious Agents and Cancer, vol. 5, article 27, 2010.

[201] H. Geddert, A. Z. Hausen, H. E. Gabbert, and M. Sarbia, “EBV-associated gastric carcinoma,” The Journal of Immunology, vol. 193, no. 7, pp. 3566–3576, 2014.

[202] D. N. Martínez-Carrillo, J. Atrisco-Morales, R. Hernández-Pando et al., “Helicobacter pylori vacA and cagA genotype diversity and interferon gamma expression in patients with chronic gastritis and patients with gastric cancer,” Revista de Gastroenterología de Mexico, vol. 79, no. 4, pp. 220–228, 2014.

[203] C. Zhao, X. Lu, X. Bu et al., “Involvement of tumor necrosis factor-α in the upregulation of CXC chemokine expression in gastric cancer induced by Helicobacter pylori,” BMC Cancer, vol. 10, article 419, 2010.

[204] J. H. Son, J. C. Rhee, D. Park et al., “Inducible nitric oxide synthase expression in gastroduodenal diseases infected with Helicobacter pylori,” Helicobacter, vol. 6, no. 1, pp. 37–43, 2001.

[205] K. Robinson, R. H. Argent, and J. C. Atherton, “The inflammatory and immune response to Helicobacter pylori infection,” Best Practice and Research: Clinical Gastroenterology, vol. 21, no. 2, pp. 237–259, 2007.

[206] J. Shen, Z. Xiao, W. K. K. Wu et al., “Epigenetic silencing of miR-490-3p reactivates the chromatin remodeler SMARCD1 to promote helicobacter pylori-induced gastric carcinogenesis,” Cancer Research, vol. 75, no. 4, pp. 754–765, 2015.

[207] J. H. Yoon, Y. Choi, S. Choi et al., “GKN1-miR-185-DNMT1 axis suppresses gastric carcinogenesis through regulation of epigenetic alteration and cell cycle,” Clinical Cancer Research, vol. 19, no. 17, pp. 4599–4610, 2013.

[208] A. S. L. Cheng, M. S. Li, W. Kang et al., “Helicobacter pylori causes epigenetic dysregulation of FOXD3 to promote gastric carcinogenesis,” Gastroenterology, vol. 144, no. 1, pp. 122–133, e9, 2013.

[209] Y. Saito, N. Murata-Kamiya, T. Hirayama, Y. Ohba, and M. Hatakeyama, “Conversion of Helicobacter pylori CagA from senescence inducer to oncogenic driver through polarity-dependent regulation of p21,” Journal of Experimental Medicine, vol. 207, no. 10, pp. 2157–2174, 2010.

[210] K. Matsushima, H. Isomoto, N. Inoue et al., “MicroRNA signatures in Helicobacter pylori-infected gastric mucosa,” International Journal of Cancer, vol. 128, no. 2, pp. 361–370, 2011.

[211] Q. Yang, Z. Jie, H. Cao et al., “Low-level expression of let-7a in gastric cancer and its involvement in tumorigenesis by targeting RAB40C,” Carcinogenesis, vol. 32, no. 5, pp. 713–722, 2011.

[212] S. Myllýkangas, O. Monni, B. Nagy, H. Rautelin, and S. Knuutila, “Helicobacter pylori infection activates FOS and stress-response genes and alters expression of genes in gastric cancer-specific loci,” Genes Chromosomes and Cancer, vol. 40, no. 4, pp. 334–341, 2004.

[213] E. Y. Cho, K. Park, I. Do et al., “Heterogeneity of ERBB2 in gastric carcinomas: a study of tissue microarray and matched primary and metastatic carcinomas,” Modern Pathology, vol. 26, no. 5, pp. 677–684, 2013.

[214] R. Chaturvedi, M. Asim, M. B. Piazuelo et al., “Activation of EGFR and ERBB2 by Helicobacter pylori results in survival of...
gastric epithelial cells with DNA damage," *Gastroenterology*, vol. 146, no. 7, pp. 1739–1751.e14, 2014.

[229] H. Wong and T. Yau, “Molecular targeted therapies in advanced gastric cancer: does tumor histology matter?”, *Therapeutic Advances in Gastroenterology*, vol. 6, no. 1, pp. 15–31, 2013.

[230] M. Poppe, S. M. Feller, G. Römer, and S. Wessler, “Phosphorylation of Helicobacter pylori CagA by c-Ab1 leads to cell motility?”, *Oncogene*, vol. 26, no. 24, pp. 3462–3472, 2007.

[231] L. M. Krisch, G. Posselt, P. Hammerl, and S. Wessler, “CagA phosphorylation in *Helicobacter pylori*-infected B cells is mediated by the nonreceptor tyrosine kinases of the Src and Abb families,” *Infection and Immunity*, vol. 84, no. 9, pp. 2671–2680, 2016.

[232] C. Gao, Z. Zhang, W. Liu, S. Xiao, W. Gu, and H. Lu, “Reduced MicroRNA-218 expression is associated with high nuclear factor kappa B activation in gastric cancer,” *Cancer*, vol. 116, no. 1, pp. 41–49, 2010.

[233] J.-Y. Piao, H. G. Lee, S.-J. Kim et al., “*Helicobacter pylori* activates IL-6–STAT3 signaling in human gastric cancer cells: potential roles for reactive oxygen species?”, *Helicobacter*, vol. 21, no. 5, pp. 405–416, 2016.

[234] L. Miao, K. Liu, M. Xie, Y. Xing, and T. Xi, “miR-375 inhibits gastric cancer cell growth and tumorigenesis by direct repression of miR-222 simultaneously target RECK and regulate growth and invasion of gastric cancer cells,” *Medical Science Monitor*, vol. 21, pp. 2718–2725, 2015.

[235] W.-C. Lin, H.-F. Tsai, H.-J. Liao et al., “Regulation of Noxa-mediated apoptosis in gastric cancer cells through TRAF6- and JNK-mediated signaling,” *FASEB Journal*, vol. 25, no. 3, pp. 957–966, 2011.

[236] S. R. Rath, L. Das, S. B. Kokate et al., “Regulation of Bcl-2 family proteins by miRNA-218 in gastric cancer cells,” *FEBS Letters*, vol. 581, pp. 258–264, 2014.

[237] C.-C. Liu and H.-L. Lu, “Reduced microRNA-218 expression is associated with high nuclear factor κB activation in gastric cancer,” *Oncogene*, vol. 305, no. 6, pp. 553–562, 2015.

[238] Y. Akazawa, K. Matsuda, H. Isomoto et al., “miR-375 inhibits gastric cancer cell growth and tumorigenesis by direct repression of miR-222 simultaneously target RECK and regulate growth and invasion of gastric cancer cells,” *Cancer Science*, vol. 106, no. 10, pp. 1833–1842, 2015.

[239] S. Sue, W. Shibata, and S. Maeda, “Helicobacter pylori-induced signaling pathways contribute to intestinal metaplasia and gastric carcinogenesis,” *BioMed Research International*, vol. 2015, Article ID 737621, 9 pages, 2015.

[240] R. Barros, B. Pereira, I. Duluc et al., “Key elements of the BMP/SMAD pathway co-localize with CDX2 in intestinal metaplasia and regulate CDX2 expression in human gastric cancer cells,” *Journal of Pathology*, vol. 263, no. 4, pp. 411–420, 2008.

[241] W.-C. Lin, H.-F. Tsai, H.-J. Liao et al., “Helicobacter pylori sensitizes TNF-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in human gastric epithelial cells through regulation of FLIP,” *Cell Death and Disease*, vol. 5, no. 3, Article ID e109, 2014.

[242] L. M. Kristch, G. Posselt, P. Hammerl, and S. Wessler, “CagA modulates host immune response,” *Infection and Immunity*, vol. 84, no. 9, pp. 2671–2680, 2016.

[243] L. G. Qui, X. Li, C. Wei et al., “The prognostic role of SIRT1-autophagy axis in gastric cancer,” *Cancer Biology & Therapy*, vol. 161, no. 1, pp. 49–58, 2006.

[244] A. Lamb, X.-D. Yang, Y.-H. N. Tsang et al., “Helicobacter pylori CagA activates NF-κB by targeting TAK1 for TRAF6-mediated ubiquitination,” *EMBO Reports*, vol. 10, no. 11, pp. 1242–1249, 2009.

[245] J. M. Noto and R. M. Peek, “The role of microRNAs in *Helicobacter pylori* pathogenesis and gastric carcinogenesis,” *Frontiers in Cellular and Infection Microbiology*, vol. 1, article 21, 2011.

[246] X. Zhou, Y. Xia, L. Li, and G. Zhang, “MiR-101 inhibits cell growth and tumorigenesis of *Helicobacter pylori* related gastric cancer by repression of SOCS2,” *Cancer Biology & Therapy*, vol. 16, no. 1, pp. 160–169, 2015.

[247] W. Liu, N. Song, H. Yao, L. Zhao, H. Liu, and G. Li, “miR-221 and miR-222 simultaneously target RECK and regulate growth and invasion of gastric cancer cells,” *Medical Science Monitor*, vol. 21, pp. 2718–2725, 2015.

[248] Y. Akazawa, K. Matsuda, H. Isomoto et al., “BH3-only protein Bim is associated with the degree of *Helicobacter pylori*-induced gastritis and is localized to the mitochondria of inflammatory cells in the gastric mucosa,” *International Journal of Medical Microbiology*, vol. 305, no. 6, pp. 553–562, 2015.

[249] S. Rath, L. Das, S. B. Kokate et al., “Regulation of Noxa-mediated apoptosis in *Helicobacter pylori*-infected gastric epithelial cells,” *FASEB Journal*, vol. 29, no. 3, pp. 796–806, 2015.

[250] A. Yanai, Y. Hirata, Y. Mitsuno et al., “Helicobacter pylori induces antiapoptosis through nuclear factor-κB activation,” *Journal of Infectious Diseases*, vol. 188, no. 11, pp. 1741–1751, 2003.

[251] C. C. King and M. Obonyo, “Helicobacter pylori modulates host cell survival regulation through the serine-threonine kinase, 3-phosphoinositide dependent kinase 1 (PDK-1),” *BMC Microbiology*, vol. 15, no. 1, article 222, 2015.

[252] N. Li, C. Xie, and N.-H. Lu, “Transforming growth factor-β: an important mediator in Helicobacter pylori-associated pathogenesis,” *Frontiers in Cellular and Infection Microbiology*, vol. 5, article 77, 2015.

[253] Y. S. O. Lee, D. Y. E. Lee, D. Y. E. Yu, S. Kim, and Y. C. H. Lee, “Helicobacter pylori induces cell migration and invasion through casein kinase 2 in gastric epithelial cells,” *Helicobacter*, vol. 19, no. 6, pp. 465–475, 2014.

[254] H. Jiang, Y. Zhou, Q. Liao, and H. Ouyang, “Helicobacter pylori infection promotes the invasion and metastasis of gastric cancer through increasing the expression of matrix metalloproteinase-1 and matrix metalloproteinase-10,” *Experimental and Therapeutic Medicine*, vol. 8, no. 3, pp. 769–774, 2014.

[255] A. M. Costa, R. M. Ferreira, I. Pinto-Ribeiro et al., “Helicobacter pylori activates matrix metalloproteinase 10 in gastric epithelial cells via EGFR and ERK-mediated pathways,” *Journal of Infectious Diseases*, vol. 213, no. 11, pp. 1767–1776, 2016.

[256] M. Fassan, D. Saraggi, L. Balsamo et al., “Let-7c down-regulation in *Helicobacter pylori*-related gastric carcinogenesis,” *Oncotarget*, vol. 7, no. 4, pp. 4915–4924, 2016.

[257] L. Zha, J. Zhang, W. Tang et al., “HMGA2 elicits EMT by activating the Wnt/β-catenin pathway in gastric cancer;” *Diseases and Sciences*, vol. 58, no. 3, pp. 724–733, 2013.

[258] T. Huang, W. Kang, A. S. L. Cheng, J. Yu, and K. F. To, “The emerging role of Slit-Robo pathway in gastric and other gastrointestinal cancers,” *BMC Cancer*, vol. 15, no. 1, article 950, 2015.

[259] Y. Hayashi, M. Tsuji, J. Wang et al., “CagA mediates epigenetic regulation to attenuate let-7 expression in *Helicobacter pylori*-related carcinogenesis,” *Gut*, vol. 62, no. 11, pp. 1536–1546, 2013.

[260] M. Noormohammad, S. Sadeghi, H. Tabatabaeian et al., “Upregulation of miR-222 in both *Helicobacter pylori*-infected and noninfected gastric cancer patients,” *Journal of Genetics*, vol. 95, no. 4, pp. 991–995, 2016.
for non-invasive diagnosis and prognostic assessment of gastric cancer; PeerJ, vol. 4, Article ID e2112, 2016.

[289] B. G. Schneider, M. B. Piazuelo, L. A. Sicinschi et al., "Virulence of infecting Helicobacter pylori strains and intensity of mononuclear cell infiltration are associated with levels of DNA hypermethylation in gastric mucosa;" Epigenetics, vol. 8, no. 11, pp. 1153–1161, 2013.

[290] W. K. K. Wu, J. Yu, M. T. V. Chan, K. F. To, and A. S. L. Cheng, "Combinatorial epigenetic deregulation by Helicobacter pylori and Epstein–Barr virus infections in gastric tumourgenesis;" Journal of Pathology, vol. 239, no. 3, pp. 245–249, 2016.

[291] G. M. Buzás and J. Konderák, "Co-infection with Helicobacter pylori and Epstein-Barr virus in benign upper digestive diseases: an endoscopic and serologic pilot study;" United European Gastroenterology Journal, vol. 4, no. 3, pp. 388–394, 2016.

[292] S. K. Shukla, J. Khatoon, K. N. Prasad et al., "Transforming growth factor beta 1 (TGF-𝛽) modulates Epstein-Barr virus reactivation in absence of Helicobacter pylori infection in patients with gastric cancer;" Cytokine, vol. 77, pp. 176–179, 2016.